MedTrace Logo

HER2-Peptide Vaccination of Patients With Solid Tumors

NCT02276300 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-11-20

No results posted yet for this study

Summary

Investigation of peptide vaccination targeting HER2/neu in patients with metastasized breast or gastric cancer with moderate HER2/neu expression.

Conditions

Interventions

DRUG

Cyclophosphamide

Treatment of mild Endoxan application three days before Her2 vaccination

DRUG

Sargramostim

Sargramostim is part of Her2 vaccination

DRUG

HER2-Peptid-Vakzine

Her2 vaccination is supplemented by Sargramostim and Aldara Creme application

DRUG

Imiquimod

Imiquimod is part of Her2 vaccination

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Angela Krackhardt, Prof.Dr.med. · III.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-07-18
Completion
2018-07-13

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02276300 on ClinicalTrials.gov